FIGURE

Figure 4

ID

ZDB-FIG-191230-912

Publication

Cheng et al., 2019 - Ciglitazone-a human PPARγ agonist-disrupts dorsoventral patterning in zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Figure 4

Knockdown of pparγ does not block ciglitazone-induced toxicity at 24 hpf.

Mean (± standard deviation) percent of normal, ventralized, delayed, or dead embryos following injection of nc-MOs or pparγ-MOs at 0.75 hpf and exposure from 4 to 24 hpf to vehicle (0.2% DMSO) or 12.5 µM ciglitazone (Cig) (N = 60 embryos per treatment). Asterisk (*) denotes a significant difference (p < 0.05) in the percent of normal embryos relative to within-treatment water-injected controls (p < 0.05). Cross (†) denotes a significant difference (p < 0.05) in the percent of normal embryos relative to within-MO vehicle (0.2% DMSO) controls. chd-MO was used as a positive control for ventralization (A). Representative images of nc-MO- and pparγ-MO-injected embryos exposed to either vehicle (0.2% DMSO) or 12.5 µM Cig at 24 hpf (B–G).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	WT WT + MO1-chrd WT + MO3-pparg
Condition:	chemical treatment by environment: ciglitazone
Knockdown Reagents:	MO1-chrd MO3-pparg
Observed In:	embryo development ending in birth or egg hatching whole organism
Stage:	Prim-5

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Peer J.